We have compiled a list of manufacturers, distributors, product information, reference prices, and rankings for medicine.
ipros is IPROS GMS ・ IPROS One of the largest technical database sites in Japan that collects information on.

medicine Product List and Ranking from 26 Manufacturers, Suppliers and Companies

Last Updated： Aggregation Period:Aug 13, 2025～Sep 09, 2025
This ranking is based on the number of page views on our site.

medicine Manufacturer, Suppliers and Company Rankings

Last Updated： Aggregation Period:Aug 13, 2025～Sep 09, 2025
This ranking is based on the number of page views on our site.

  1. マーケットリサーチセンター Tokyo//Service Industry
  2. 関東化学株式会社 Tokyo//Chemical バイオケミカル部
  3. null/null
  4. 4 キャタレント・ジャパン Tokyo//Manufacturing and processing contract
  5. 5 カツマタ Shizuoka//Medical and Welfare 医薬品製造販売部
Go to Company Ranking

medicine Product ranking

Last Updated： Aggregation Period:Aug 13, 2025～Sep 09, 2025
This ranking is based on the number of page views on our site.

  1. For various titrations! The titration "indicator" specified in JIS K8001. 関東化学株式会社 バイオケミカル部
  2. Development of various types of medium-sized molecule (nucleic acid, peptide) pharmaceuticals (processes, analytical methods, etc.)
  3. Global Procurement of Reference Drugs <From Drug Procurement to Problem Solving> キャタレント・ジャパン
  4. Cavity prevention medicine Gurupepr カツマタ 医薬品製造販売部
  5. 4 Pharmaceutical CDMO services 大塚化学

medicine Product List

136～150 item / All 516 items

Displayed results
[Market Report] Global Market for Pulmonary Arterial Hypertension

[Market Report] Global Market for Pulmonary Arterial Hypertension

The global market for pulmonary arterial hypertension is projected to reach 10.8 billion dollars by 2031.

The global pulmonary arterial hypertension (PAH) market reached a revenue of $7 billion in 2022 and is aiming for significant growth. Projections indicate that the market will reach $10.8 billion by 2031, with a compound annual growth rate (CAGR) of 5% from 2023 to 2031. This growth reflects the increasing demand for effective treatments for this serious and life-threatening disease. Pulmonary arterial hypertension is a rare but severe condition characterized by high blood pressure in the lungs. It involves narrowing or blockage of the pulmonary arteries and capillaries, leading to increased strain on the heart and gradually worsening symptoms. Without timely and effective treatment, PAH can be life-threatening, highlighting the urgent need for advanced treatment options. For application methods, please check the [PDF download] button or apply directly through the related links.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
[Market Report] Global Diabetic Nephropathy Market

[Market Report] Global Diabetic Nephropathy Market

The global diabetic nephropathy market is advancing in the fight against kidney disease, expected to reach 3.37 billion USD by 2031.

The global diabetic nephropathy market is at the forefront of combating kidney disorders in diabetic patients, offering hope and advanced treatment options. According to recent market reports, the global diabetic nephropathy market generated approximately $2 billion in revenue in 2022 and is estimated to surge to about $3.37 billion by 2031. This noteworthy growth trajectory is driven by a solid annual compound growth rate (CAGR) of 6% projected from 2023 to 2031. Diabetic nephropathy, a long-term kidney disorder, is a significant concern for those living with diabetes. This condition occurs when persistently elevated blood sugar levels cause damage to kidney function. Diabetic nephropathy can affect patients with type 2 diabetes and is primarily characterized by damage to the smallest blood vessels in the kidneys. When these small blood vessels are damaged, proteins begin to leak into the urine from both kidneys, indicating renal dysfunction. You can check the application method by clicking the [PDF Download] button or apply directly through the related links.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
[Market Report] Global Nucleic Acid Medicine Market

[Market Report] Global Nucleic Acid Medicine Market

Global Nucleic Acid Drug Market: Expected to Reach 12 Billion USD by 2031 Due to Advances in Precision Medicine and Targeted Therapies.

The global nucleic acid therapeutics market is at the forefront of the pharmaceutical industry's push towards precision medicine and targeted therapies. According to recent market reports, the global nucleic acid therapeutics market is estimated to achieve approximately $4.5 billion in revenue by 2022 and surge to $12 billion by 2031. This remarkable growth trajectory is driven by powerful compounds. The compound annual growth rate (CAGR) is projected to be 11.6% from 2023 to 2031. Nucleic acid therapeutics encompass a wide range of innovative treatments, including ribonucleic acid (RNA) therapeutics and deoxyribonucleic acid (DNA) therapeutics. These therapies further include enzymes, antisense oligonucleotides, DNA aptamers, ribozymes, micro RNA, RNA decoys, and short interfering RNA, all designed to target disease-causing genes while preserving healthy cells and tissues. For application methods, please check the [PDF download] button or apply directly through the related links.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
[Market Report] Global Lyme Disease Treatment Market

[Market Report] Global Lyme Disease Treatment Market

The global Lyme disease treatment market is expected to achieve steady growth, reaching 1.652 billion USD by 2031.

The global Lyme disease treatment market is aiming for significant expansion, with revenues reaching approximately $799.4 million in 2022. Recent market analysis indicates that this sector is expected to experience a robust compound annual growth rate (CAGR) of 8.4% in 2022. The forecast period is from 2023 to 2031, with an estimated value of $1.652 billion by 2031. This increase is attributed to the rising global prevalence of Lyme disease and the development of innovative treatments. As the prevalence of Lyme disease continues to rise and research efforts focus on developing more effective treatment options, the global Lyme disease treatment market is poised for continuous growth. Increased investment in research and development, expanded access to healthcare, and heightened awareness of Lyme disease among healthcare professionals and the general public are expected to lead to significant advancements in the diagnosis and treatment of this debilitating disease. For application methods, please check the [PDF download] button or apply directly through the related links.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Methods for artificially controlling the blood-brain barrier function - Overcoming refractory neurological disorders.

Methods for artificially controlling the blood-brain barrier function - Overcoming refractory neurological disorders.

We have discovered functional molecules that artificially and reversibly open and close the blood-brain barrier.

*Looking for partner companies for joint development* The blood-brain barrier (BBB) has an important function in preventing harmful substances from entering the brain and maintaining a healthy environment within it. However, due to the presence of the BBB, water-soluble drugs administered peripherally cannot be delivered to the brain, and conversely, it has not been possible to restore the function of the BBB once it has opened due to pathological conditions such as neurodegenerative diseases. Recently, Yamaguchi University has established a method to artificially and reversibly open and close the BBB. By identifying the key factors involved in the opening and closing of the BBB and utilizing its physiological functions, it is now possible to reversibly open the BBB under conditions with minimal concerns about side effects, paving the way for drug delivery to the brain, which has been challenging. Additionally, restoring the function of the pathologically opened BBB is expected to improve disease conditions. <Target Diseases> - Closing an opened BBB: cerebral infarction, diabetic retinopathy, Alzheimer's disease, Parkinson's disease, etc. - Opening a closed BBB: brain tumors, neurological diseases, etc. <Benefits for Companies> - The development of new, highly safe therapeutic drugs is now possible through a novel mechanism that allows for the artificial and reversible opening and closing of the BBB.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Innovative AI drug discovery

Innovative AI drug discovery

What does the fusion of medical big data and AI (artificial intelligence) bring to the field of drug discovery? A detailed explanation of the current state and challenges of innovative drug discovery technologies!

Exploring the potential of AI drug discovery through the efforts of pharmaceutical companies, starting with large-scale projects!

  • Technical and Reference Books
  • Analytical Equipment and Devices
  • Other information systems

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Tateyama Chemical Co., Ltd. Quality Assurance System

Tateyama Chemical Co., Ltd. Quality Assurance System

With "creative practice" as a keyword, we are constantly reevaluating our quality assurance system.

Our company started with the production of methyl ephedrine, an active pharmaceutical ingredient (API) for expectorants. The manufacturing of APIs and their quality control are the very roots of Tateyama Chemical. Aiming for world-class quality assurance, we achieve global-level quality assurance that complies not only with Japan's GMP, which is the standard for pharmaceutical manufacturing and quality control, but also with PIC/S GMP, to supply safe, effective, and high-quality pharmaceuticals to countries around the world. To respond to the trust of various customers and ultimately the end users, we will continuously update our quality control system. 【Management Policy】 ■ Development of new products ■ Refinement of technology ■ Thorough implementation of 5S and quality control ■ Raising awareness of environmental conservation and health and safety *For more details, please refer to the PDF materials or feel free to contact us.

  • Contract manufacturing
  • Chemicals

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Global Procurement of Reference Drugs <From Drug Procurement to Problem Solving>

Global Procurement of Reference Drugs <From Drug Procurement to Problem Solving>

Caterpillar provides solutions, support, and specialized services for pharmaceutical challenges tailored to customer needs in various regions around the world.

Our sourcing specialist team leverages a global network of major manufacturers and key wholesalers to efficiently procure a variety of pharmaceuticals, even for items that are difficult to source, in the quantities you require. CatTalent delivers comparator drugs promptly to any location around the world through its global storage and distribution network for clinical trial drugs. Whether you only need procurement of comparator drugs or require comprehensive services such as over-encapsulation, blinding, packaging and labeling, storage and distribution, or regulatory consulting, we can customize procurement-related services to meet your needs.

  • Contract manufacturing

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Natural Proteoglycan, the Herbal Medicine of the Sea

Natural Proteoglycan, the Herbal Medicine of the Sea

Safe and secure materials! Ideal for use as ingredients in cosmetics and health foods.

"Natural Proteoglycan" is a safe and reliable material that can be taken orally. The raw material is salmon nasal cartilage, sourced entirely from salmon caught in Hokkaido. There are no concerns about BSE or foot-and-mouth disease, which are characteristic of mammals such as cows and pigs, nor is there any worry about avian influenza from birds. Additionally, we do not use farmed salmon that have been administered antibiotics. All reagents used in the extraction and purification processes are approved as food additives. 【Features】 ○ Safe and reliable material ○ Free from risk of side effects ○ High purity, tasteless and odorless ○ Non-heating manufacturing method ○ Free from additives For more details, please contact us or download the catalog.

  • Organic Natural Materials

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Search Keywords Related to medicine

COPYRIGHT © 2001-2025 IPROS CORPORATION ALL RIGHTS RESERVED.